Allogene Therapeutics (ALLO) Financials

Allogene Therapeutics (NASDAQ: ALLO) remains a cash-rich clinical-stage biotech, but the latest numbers show a company still burning meaningful cash with no product revenue. Over the last several years, ALLO has continued to fund research and development through its balance sheet and periodic equity issuance, while operating losses have stayed substantial.

What stands out most in Q1 2026:

• The company ended Q1 2026 with $266.9 million in cash, cash equivalents, and short-term investments, which provides a sizable liquidity cushion.
• Investments still represent the bulk of liquid assets, suggesting management is keeping capital parked in relatively safe instruments rather than spending it aggressively on fixed assets.
• Interest and investment income of $3.6 million helped offset a portion of operating losses.
• Shares outstanding were lower than in some prior periods, though share count remains elevated versus early 2024 levels.
• Total assets were $396.0 million in Q1 2026, while total liabilities were $117.1 million, leaving common equity of $278.9 million.
• The company continues to carry a large accumulated deficit, with retained earnings at negative $2.05 billion, which is typical for a pre-commercial biotech but still reflects years of losses.
• Capital spending was minimal in Q1 2026, with only $9,000 spent on property and equipment.
• ALLO reported no revenue in Q1 2026, so the business is still entirely dependent on financing and investment income.
• Operating expenses totaled $46.1 million in Q1 2026, driven by $32.0 million of R&D and $14.1 million of SG&A.
• The company posted a net loss of $42.6 million for the quarter, or $0.18 per share, underscoring continued cash burn.

Trend analysis over the last four years:

ALLO’s financial profile has been defined by a familiar biotech pattern: large operating losses, no commercial revenue, and a reliance on financing activity to extend the runway. From 2023 through early 2026, quarterly revenue remained effectively zero aside from immaterial amounts in some older periods, while R&D spending consistently stayed high as the company advanced its cell therapy pipeline.

Cash usage has also been persistent. In Q1 2025, operating cash outflow was $52.9 million; by Q4 2025 it improved to $27.6 million; and in Q1 2026 it was $12.9 million. That’s an improvement, but the company is still consuming cash rather than generating it. A key driver of the improvement appears to be lower reported losses and non-cash adjustments, not a fundamental shift to profitability.

The balance sheet has also contracted significantly since 2024. Total assets were $746.9 million in Q1 2024, but fell to $396.0 million by Q1 2026. Most of that decline reflects lower cash and investment balances as the company funds operations. Total equity also dropped from $461.4 million in Q1 2024 to $278.9 million in Q1 2026.

One encouraging point is that ALLO still has enough liquidity to keep operating for now. Cash and investments at quarter-end appear well above current liabilities, and the company has not taken on meaningful debt. But the longer-term picture remains dependent on clinical progress, cost discipline, and future financing access.

Bottom line: Allogene Therapeutics remains a speculative biotech story. The company has a solid cash position for now, but the absence of revenue and ongoing quarterly losses mean investors should continue to expect dilution risk and heavy dependence on clinical trial results.